STC2 Is a Potential Prognostic Biomarker for Pancreatic Cancer and Promotes Migration and Invasion by Inducing Epithelial–Mesenchymal Transition
Figure 1
STC2 was overexpressed in pancreatic cancer tissues and correlated with the development and progression of cancer. (a) qRT-PCR was subjected to analyze the different mRNA expression of STC2 in the 98 cases of pancreatic cancer tissues and corresponding normal tissues. (b) The protein expression of STC2 in the specimens from pancreatic cancer patients. Immunohistochemistry staining with anti-STC2 antibody in tumor and surrounding normal tissues. (c) The patients were divided into two groups according to the tumor size, and the mRNA expression of STC2 was assessed in the two groups. (d) The mRNA expression of STC2 was analyzed in pancreatic cancer patients with or without lymph node metastasis. (e) The patients were divided into two groups based on the expression levels of STC2, and the five-year survival rate was determined during follow-up. (d) The AUC curve was used to evaluate the value of STC2 as a diagnosis biomarker for pancreatic carcinoma. P<0.001 was defined as very significant difference.